GRI Bio GRI 深沪

等待开盘 09-16 09:30:00 美东时间

1.86

+0.050

+2.76%

华盛通

立即下载

最高1.96
今开1.81
成交量 37.48万股
最低 1.78
昨收 1.81
总市值 544.55万
52周最高 30.43
市盈率 ^静 --
换手率 12.80%
52周最低 1.10
委比 66.45%
总股本 292.77万
历史最高 2314002.60
量比 0.03
振幅 9.94%
历史最低 1.78
每手 1
风险率 5.12%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

GRI Bio Reports Interim 6-Week Lung Function Results From Ongoing Phase 2a Study Evaluating GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis; Phase 2a Study Fully Enrolled; Topline Data On Track For Q3 2025

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker dataPhase 2a study fully enrolled; Topline data on track for Q3 2025Currently available treatments for IPF

09-11 20:47
Silvercorp Publishes Fiscal 2025 Sustainability Report

Trading Symbol: TSX/NYSE American: SVM VANCOUVER, BC, Sept. 10, 2025 /PRNewswire/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) is pleased to annou...

09-11 08:03
上市公司可持续发展或ESG报告中环境议题选择与披露实践研究——以汽车行业上市公司为例

登录新浪财经APP 搜索【信披】查看更多考评等级在全球经济格局深度重塑与国际治理体系加速变革的时代背景下，可持续发展理念及环境、社会和治理...

09-03 17:31
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

On September 9, 2025, at 3:00 PM ET, GRI Bio, Inc.'s CEO, Marc Hertz, PhD, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York. The presentation will be live-streamed on the company’s website and available for 90 days post-event. GRI Bio, a biopharmaceutical company, focuses on NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases.

09-03 13:00
Health Catalyst Announces Winners of the 2025 Catalyst Awards

Recognizing Healthcare's Data-Driven Innovators at the 2025 Health Catalyst Analytics Summit SALT LAKE CITY, Aug. 29, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: H...

08-29 21:00
港E声|数据获取难、回报周期长？五招搞定ESG与财报联动常见难点

本文来源：时代商业研究院作者：祝箐来源丨时代商业研究院作者丨特约研究员祝箐作为亚洲金融中心，香港在ESG信息披露方面一直走在前列。据商道咨询数...

08-25 20:53
GRI Bio Advances with Positive GRI-0621 Data

GRI Bio ( ($GRI) ) just unveiled an announcement. GRI Bio‘s recent corporate pr...

08-20 21:49
【西部非银】保险业“洗尽铅华”系列一：中国保险资管研究，发展历程、海外镜鉴与未来趋势

（来源：西部证券研究发展中心）核心结论核心结论：在行业周期波动与转型深化下，保险业逐步回归本源，保险资管作为保险业资金管理的核心载体，亦迎来转型重塑...

08-20 16:34
和黄医药(00013)完成沃瑞沙和泰瑞沙联合疗法用于一线治疗特定肺癌患者的SANOVO中国III期研究患者入组

金吾资讯

08-20 08:46
Ground Rents Income Fund PLC Appoints New Auditor

Ground Rents Income Fund ( ($GB:GRIO) ) has shared an announcement. Ground Rent...

08-15 00:22

派息除权日	每股总股息	派息日期
2023-03-23	0.63	2023-03-28
2022-12-22	0.53	2022-12-29
2022-09-22	0.45	2022-09-29
2022-06-23	0.48	2022-06-30
2022-03-24	0.52	2022-03-31
2021-12-22	0.56	2021-12-29
2021-09-23	0.44	2021-09-30
2021-06-17	0.47	2021-06-24
2021-03-18	0.51	2021-03-25
2020-12-22	0.64	2020-12-30
2020-09-17	0.35	2020-09-24
2020-06-18	0.42	2020-06-25
2020-03-19	0.68	2020-03-26
2019-12-19	0.51	2019-12-27
2019-09-19	0.27	2019-09-26
2019-06-20	0.37	2019-06-27
2019-03-21	0.35	2019-03-28
2018-12-20	0.41	2018-12-27
2018-09-20	0.22	2018-09-27
2018-06-21	0.44	2018-06-28
2018-03-22	0.22	2018-03-29
2017-12-21	0.95	2017-12-28
2017-09-21	0.33	2017-09-27
2017-06-21	0.35	2017-06-28
2016-12-21	0.46	2016-12-29
2016-09-21	0.38	2016-09-28
2016-06-22	0.31	2016-06-29
2016-03-23	0.37	2016-03-31
2015-12-23	0.21	2015-12-31
2015-09-23	0.13	2015-09-30
2015-06-24	0.68	2015-07-01
2015-03-25	0.44	2015-04-01
2014-12-24	0.41	2015-01-02
2014-09-24	0.24	2014-10-01
2014-06-25	0.39	2014-07-02
2014-03-26	0.22	2014-04-02
2013-12-26	0.17	2014-01-03
2013-09-25	0.23	2013-10-02
2012-12-26	2.23	2013-01-03
2012-09-26	0.23	2012-10-03
2012-06-20	0.26	2012-06-27
2012-03-21	0.15	2012-03-28
2011-12-21	0.18	2011-12-28
2011-09-21	0.20	2011-09-28
2011-06-22	0.28	2011-06-29
2011-03-23	0.61	2011-03-30
2010-12-21	1.12	2010-12-29
2010-09-22	0.18	2010-09-29
2010-06-23	0.21	2010-06-30
2010-03-24	0.43	2010-03-31
2009-12-29	1.03	2010-01-06
2009-09-29	0.08	2009-10-06
2009-06-29	0.57	2009-07-07
2008-12-29	0.49	2009-01-05

公司名称	GRI Bio
行业分类	--
业务描述	GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

GRI Bio GRI 深 沪

1.86

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

GRI Bio GRI 深沪